Janice M Mehnert MD

PubMed

• Outcomes of concurrent versus non-concurrent immune checkpoint inhibition with stereotactic radiosurgery for melanoma brain metastases.
  Allen Ye Fu, Kenneth Bernstein, Jeff Zhang, Joshua Silverman, Janice Mehnert
  Journal of Neuro-Oncology. 2025-04-04
• Characterizing Chronic Cutaneous Immune-Related Adverse Events Following Immune Checkpoint Inhibitors.
  Kylie A Fletcher, Rachel S Goodman, Aleigha Lawless, Rachel Woodford, Faisal Fa'ak
  JAMA Dermatology. 2025-03-12
• 9 citations
  Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma.
  Omid Hamid, Karl D Lewis, Amy Weise, Meredith McKean, Kyriakos P Papadopoulos
  Journal of Clinical Oncology. 2024-08-20

Journal Articles

• Prognostic Gene Expression Profiling in Cutaneous Melanoma  
  Douglas Grossman, Sancy A Leachman, Larissa Korde, Elizabeth I Buchbinder, Emily Y Chu, Julia A Curtis, Laura K Ferris, Kenneth F Grossmann, Siwen Hu-Lieskovan, Joanne..., JAMA Dermatology
• Autophagy Maintains Tumour Growth Through Circulating Arginine  
  Janice M Mehnert, Marcus W Bosenberg, Nature
• The Challenge for Development of Valuable Immuno-Oncology Biomarkers  
  Arta M Monjazeb, Janice M Mehnert, Lyndsay N Harris, Clinical Cancer Research

Lectures

• Immunotherapy Versus BRAF/MEK Inhibitors in the Adjvuant Setting: Is There a Clear Winner? 
  ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019